{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:23:13Z","timestamp":1783077793862,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00105-026-05704-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:21:55Z","timestamp":1780395715000},"page":"473-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologikatherapie und Infektionen: Behandeln und Vorbeugen","Biologics and infections: treat and prevent"],"prefix":"10.1007","volume":"77","author":[{"given":"Galina","family":"Balakirski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Nenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"4","key":"5704_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00105-018-4156-z","volume":"69","author":"A Altenburg","year":"2018","unstructured":"Altenburg\u00a0A, Augustin\u00a0M, Zouboulis\u00a0CC (2018) Biologikanebenwirkungen bei Psoriasis. Hautarzt 69(4):290\u2013297. https:\/\/doi.org\/10.1007\/s00105-018-4156-z","journal-title":"Hautarzt"},{"issue":"7","key":"5704_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00105-018-4209-3","volume":"69","author":"D Sossau","year":"2018","unstructured":"Sossau\u00a0D, Yazdi\u00a0AS (2018) Kein erh\u00f6htes Risiko schwerer Infektionen unter Biologikatherapie bei Psoriasis. Hautarzt 69(7):609\u2013610. https:\/\/doi.org\/10.1007\/s00105-018-4209-3","journal-title":"Hautarzt"},{"issue":"3","key":"5704_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","volume":"138","author":"ZZN Yiu","year":"2018","unstructured":"Yiu\u00a0ZZN, Smith\u00a0CH, Ashcroft\u00a0DM, Lunt\u00a0M, Walton\u00a0S, Murphy\u00a0R, Reynolds\u00a0NJ, Ormerod\u00a0AD, Griffiths\u00a0CEM, Warren\u00a0RB, BADBIR Study Group (2018) Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J\u00a0Invest Dermatol 138(3):534\u2013541. https:\/\/doi.org\/10.1016\/j.jid.2017.10.005","journal-title":"J Invest Dermatol"},{"key":"5704_CR4","doi-asserted-by":"publisher","unstructured":"Balakirski G, Nenoff P (2026) Biologikatherapie und Infektionen: Verstehen und Erkennen. Dermatologie, Heidelberg. https:\/\/doi.org\/10.1007\/s00105-026-05683-5","DOI":"10.1007\/s00105-026-05683-5"},{"issue":"8","key":"5704_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058799","volume":"12","author":"C Thomas","year":"2022","unstructured":"Thomas\u00a0C, Raibouaa\u00a0A, Wollenberg\u00a0A, Capron\u00a0JP, Krucien\u00a0N, Karn\u00a0H, Tervonen\u00a0T (2022) Patient preferences for atopic dermatitis medications in the UK, France and Spain: a\u00a0discrete choice experiment. BMJ Open 12(8):e058799. https:\/\/doi.org\/10.1136\/bmjopen-2021-058799","journal-title":"BMJ Open"},{"key":"5704_CR6","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.24339","volume":"104","author":"M Ameen","year":"2024","unstructured":"Ameen\u00a0M, Alhusayen\u00a0R, Brandi\u00a0H, B\u00f8gelund\u00a0M, Jensen\u00a0HH, Reitzel\u00a0SB, Thyssen\u00a0JP (2024) Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis. Acta Derm Venereol 104:adv24339. https:\/\/doi.org\/10.2340\/actadv.v104.24339","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"5704_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","volume":"57","author":"M Fatahzadeh","year":"2007","unstructured":"Fatahzadeh\u00a0M, Schwartz\u00a0RA (2007) Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J\u00a0Am Acad Dermatol 57(5):737\u2013763. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.027","journal-title":"J Am Acad Dermatol"},{"key":"5704_CR8","unstructured":"Deutsche STI-Gesellschaft (2022) Leitfaden STI-Therapie, Diagnostik und Pr\u00e4vention der Deutschen STI-Gesellschaft, 4. Auflage.. Letzter Zugriff am 18.1.2026"},{"issue":"1","key":"5704_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/ddg.14013_g","volume":"18","author":"GE Gross","year":"2020","unstructured":"Gross\u00a0GE, Eisert\u00a0L, Doerr\u00a0HW, Fickenscher\u00a0H, Knuf\u00a0M, Maier\u00a0P, Maschke\u00a0M, M\u00fcller\u00a0R, Pleyer\u00a0U, Sch\u00e4fer\u00a0M, Sunderk\u00f6tter\u00a0C, Werner\u00a0RN, Wutzler\u00a0P, Nast\u00a0A (2020) S2k-Leitlinie zur Diagnostik und Therapie des Zoster und der Postzosterneuralgie. J\u00a0Dtsch Dermatol Ges 18(1):55\u201379. https:\/\/doi.org\/10.1111\/ddg.14013_g","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"5704_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00105-025-05538-5","volume":"76","author":"VL M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0VL, Kreuter\u00a0A, Uhrla\u00df\u00a0S, Nenoff\u00a0P (2025) Relevante Aspekte zu Candida-Spezies in der Dermatologie: Eine \u00dcbersicht [Relevant aspects of Candida species in dermatology: An overview]. Dermatologie (Heidelb) 76(9):544\u2013550. https:\/\/doi.org\/10.1007\/s00105-025-05538-5","journal-title":"Dermatologie (Heidelb)"},{"issue":"3","key":"5704_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajog.2025.03.031","volume":"233","author":"B Gardella","year":"2025","unstructured":"Gardella\u00a0B, Dominoni\u00a0M, Cassani\u00a0C, Spinillo\u00a0FP, Spinillo\u00a0A (2025) Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials. Am J Obstet Gynecol 233(3):152\u2013161. https:\/\/doi.org\/10.1016\/j.ajog.2025.03.031","journal-title":"Am J Obstet Gynecol"},{"key":"5704_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejogrb.2024.09.040","volume":"302","author":"B Gardella","year":"2024","unstructured":"Gardella\u00a0B, Cassani\u00a0C, Dominoni\u00a0M, Pasquali\u00a0MF, Spinillo\u00a0A (2024) Maintenance pharmacological therapy of recurrent vulvovaginal candidiasis. A Bayesian network meta-analysis of randomized studies. Eur J Obstet Gynecol Reprod Biol 302:310\u2013316. https:\/\/doi.org\/10.1016\/j.ejogrb.2024.09.040","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"5704_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00105-024-05410-y","volume":"75","author":"K Meier","year":"2024","unstructured":"Meier\u00a0K, Beissert\u00a0S, Ghoreschi\u00a0K, Philipp\u00a0S, Schwarz\u00a0B, Tietz\u00a0HJ, Asadullah\u00a0K (2024) Handlungsempfehlungen bei oraler Candidose unter Biologikatherapie bei Psoriasis \u2013 Ergebnisse eines Expertenmeetings. Dermatologie (Heidelb) 75(10):823\u2013826. https:\/\/doi.org\/10.1007\/s00105-024-05410-y","journal-title":"Dermatologie (Heidelb)"},{"issue":"11","key":"5704_CR14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/ddg.13130","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"Sunderk\u00f6tter\u00a0C, Feldmeier\u00a0H, F\u00f6lster-Holst\u00a0R, Geisel\u00a0B, Klinke-Rehbein\u00a0S, Nast\u00a0A, Philipp\u00a0S, Sachs\u00a0B, Stingl\u00a0J, Stoevesandt\u00a0J, Hamm\u00a0H (2016) S1 guidelines on the diagnosis and treatment of scabies - short version. J\u00a0Dtsch Dermatol Ges 14(11):1155\u20131167. https:\/\/doi.org\/10.1111\/ddg.13130","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"5704_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/ddg.13790_g","volume":"17","author":"C Sunderk\u00f6tter","year":"2019","unstructured":"Sunderk\u00f6tter\u00a0C, Becker\u00a0K, Eckmann\u00a0C, Graninger\u00a0W, Kujath\u00a0P, Sch\u00f6fer\u00a0H (2019) S2k-Leitlinie Haut- und WeichgewebeinfektionenAuszug aus \u201eKalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018\u201c. J\u00a0Dtsch Dermatol Ges 17(3):345\u2013371. https:\/\/doi.org\/10.1111\/ddg.13790_g","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"5704_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ddg.16001","volume":"24","author":"A Nast","year":"2026","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M, Bachmann\u00a0F, Boehncke\u00a0WH, Cornberg\u00a0M, Geerdes-Fenge\u00a0H, H\u00e4cker\u00a0B, H\u00e4rle\u00a0P, Klaus\u00a0J, K\u00f6hm\u00a0M, K\u00f6llner\u00a0A, Mrowietz\u00a0U, Ockenfels\u00a0HM, Pennitz\u00a0A, Philipp\u00a0S, Richter\u00a0T, Rosenbach\u00a0T, Schaberg\u00a0T, Schlaeger\u00a0M, Schmid-Ott\u00a0G, Sebastian\u00a0M, Th\u00f6lken\u00a0K, von Kiedrowski\u00a0R, Willuhn\u00a0U, Zeyen\u00a0C (2026) S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations. J\u00a0Dtsch Dermatol Ges 24(2):270\u2013282. https:\/\/doi.org\/10.1111\/ddg.16001","journal-title":"J Dtsch Dermatol Ges"},{"key":"#cr-split#-5704_CR17.1","unstructured":"(2025) Fachinformation Saphnelo\u00ae 300\u202fmg"},{"key":"#cr-split#-5704_CR17.2","unstructured":"Stand Dezember 2025. https:\/\/www.fachinfo.de\/fi\/pdf\/023613. Letzter Zugriff am 15.1.2026"},{"key":"5704_CR18","unstructured":"(2025) Fachinformation MabThera\u00ae 100\u202fmg Konzentrat zur Herstellung einer Infusionsl\u00f6sung. https:\/\/www.fachinfo.de\/fi\/pdf\/002730. Letzter Zugriff am 15.1.2026"},{"key":"5704_CR19","unstructured":"Empfehlung der Deutschen Gesellschaft f\u00fcr Rheumatologie und klinische Immunologie zur Therapie mit Anifrolumab. https:\/\/www.dgrh.de\/fileadmin\/user_upload\/downloads\/05_behandeln_downloads\/therapieinformationsb%C3%B6gen\/arztformular\/Anifrolumab_Arzt_03_2026.pdf; Letzter Zugriff am 04.04.2026."},{"key":"5704_CR20","unstructured":"Empfehlung der Deutschen Gesellschaft f\u00fcr Rheumatologie und klinische Immunologie zur Therapie mit Rituximab. https:\/\/www.dgrh.de\/fileadmin\/user_upload\/downloads\/05_behandeln_downloads\/therapieinformationsb%C3%B6gen\/arztformular\/rituximab_arzt_2014_07.pdf; Letzter Zugriff am 04.04.2026."},{"issue":"7","key":"5704_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"M Cornberg","year":"2021","unstructured":"Cornberg\u00a0M, Sandmann\u00a0L, Protzer\u00a0U, Niederau\u00a0C, Tacke\u00a0F, Berg\u00a0T, Glebe\u00a0D, Jilg\u00a0W, Wedemeyer\u00a0H, Wirth\u00a0S, H\u00f6ner Zu Siederdissen\u00a0C, Lynen-Jansen\u00a0P, van Leeuwen\u00a0P, Petersen\u00a0J, Collaborators (2021) S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr. 021-11). Z\u00a0Gastroenterol 59(7):691\u2013776. https:\/\/doi.org\/10.1055\/a-1498-2512","journal-title":"Z Gastroenterol"},{"issue":"6","key":"5704_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","volume":"20","author":"S Piaserico","year":"2019","unstructured":"Piaserico\u00a0S, Messina\u00a0F, Russo\u00a0FP (2019) Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 20(6):829\u2013845. https:\/\/doi.org\/10.1007\/s40257-019-00457-3","journal-title":"Am J Clin Dermatol"},{"key":"5704_CR23","unstructured":"(2025) Fachinformation Poteligeo 4\u202fmg\/ml, Stand 13.\u00a0Mai 2025. https:\/\/www.fachinfo.de\/fi\/pdf\/022928. Letzter Zugriff am 3.1.2026"},{"key":"5704_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/PTT.S510141","volume":"15","author":"L Mateu-Arrom","year":"2025","unstructured":"Mateu-Arrom\u00a0L, Puig\u00a0L (2025) Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy. Psoriasis (Auckl) 15:127\u2013144. https:\/\/doi.org\/10.2147\/PTT.S510141","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"5704_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.dld.2020.08.041","volume":"53","author":"B Godbert","year":"2021","unstructured":"Godbert\u00a0B, Petitpain\u00a0N, Lopez\u00a0A, Nisse\u00a0YE, Gillet\u00a0P (2021) Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis 53(4):452\u2013455. https:\/\/doi.org\/10.1016\/j.dld.2020.08.041","journal-title":"Dig Liver Dis"},{"issue":"1","key":"5704_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","volume":"82","author":"HC Mon","year":"2025","unstructured":"Mon\u00a0HC, Lee\u00a0PC, Hung\u00a0YP, Hung\u00a0YW, Wu\u00a0CJ, Lee\u00a0CJ, Chi\u00a0CT, Lee\u00a0IC, Hou\u00a0MC, Huang\u00a0YH (2025) Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J\u00a0Hepatol 82(1):51\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.018","journal-title":"J Hepatol"},{"issue":"8","key":"5704_CR27","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/gutjnl-2022-327059","volume":"72","author":"CY Meng","year":"2023","unstructured":"Meng\u00a0CY, Sun\u00a0S, Liang\u00a0Y, Xu\u00a0H, Zhang\u00a0C, Zhang\u00a0M, Wang\u00a0FS, Fu\u00a0YX, Peng\u00a0H (2023) Engineered anti-PDL1 with IFN\u03b1 targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 72(8):1544\u20131554. https:\/\/doi.org\/10.1136\/gutjnl-2022-327059","journal-title":"Gut"},{"issue":"10304","key":"5704_CR28","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino\u00a0MS, Larkin\u00a0J, Long\u00a0GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X","journal-title":"Lancet"},{"key":"5704_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103840","volume":"76","author":"C Gubser","year":"2022","unstructured":"Gubser\u00a0C, Chiu\u00a0C, Lewin\u00a0SR, Rasmussen\u00a0TA (2022) Immune checkpoint blockade in HIV. EBioMedicine 76:103840. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103840","journal-title":"EBioMedicine"},{"key":"#cr-split#-5704_CR30.1","unstructured":"(2025) Fachinformation Benlysta\u00ae 200\u202fmg"},{"key":"#cr-split#-5704_CR30.2","unstructured":"Stand Juli 2025. https:\/\/www.fachinfo.de\/fi\/pdf\/021834\/benlysta-200-mg-injektionsloesung-im-fertigpen. Letzter Zugriff am 20.1.2026"},{"issue":"5","key":"5704_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","volume":"6","author":"M Hertl","year":"2008","unstructured":"Hertl\u00a0M, Zillikens\u00a0D, Borradori\u00a0L, Bruckner-Tuderman\u00a0L, Burckhard\u00a0H, Eming\u00a0R, Engert\u00a0A, Goebeler\u00a0M, Hofmann\u00a0S, Hunzelmann\u00a0N, Karlhofer\u00a0F, Kautz\u00a0O, Lippert\u00a0U, Niedermeier\u00a0A, Nitschke\u00a0M, Pf\u00fctze\u00a0M, Reiser\u00a0M, Rose\u00a0C, Schmidt\u00a0E, Shimanovich\u00a0I, Sticherling\u00a0M, Wolff-Franke\u00a0S (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J\u00a0Dtsch Dermatol Ges 6(5):366\u2013373. https:\/\/doi.org\/10.1111\/j.1610-0387.2007.06602.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"5704_CR32","unstructured":"(2025) Fachinformation ADCETRIS 50\u202fmg. https:\/\/www.fachinfo.de\/fi\/detail\/014234\/adcetris-r. Letzter Zugriff am 10.1.2026"},{"issue":"03","key":"5704_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/a-0986-6481","volume":"46","author":"P Elsner","year":"2020","unstructured":"Elsner\u00a0P, Pfister\u00a0W, Schliemann\u00a0S (2020) Zertifizierung: \u201eImpfen f\u00fcr Dermatologen (DDA)\u201c. Aktuelle Dermatologie 46(03):83\u201386. https:\/\/doi.org\/10.1055\/a-0986-6481","journal-title":"Aktuelle Dermatologie"},{"issue":"11","key":"5704_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00105-024-05400-0","volume":"75","author":"S Schrenker","year":"2024","unstructured":"Schrenker\u00a0S, Erpenbeck\u00a0L (2024) Aktuelles zu Impfungen und Immunisierungsstrategien in der Dermatologie. Dermatologie (Heidelb) 75(11):889\u2013901. https:\/\/doi.org\/10.1007\/s00105-024-05400-0","journal-title":"Dermatologie (Heidelb)"},{"issue":"2","key":"5704_CR35","first-page":"272","volume":"34","author":"JL Kaine","year":"2007","unstructured":"Kaine\u00a0JL, Kivitz\u00a0AJ, Birbara\u00a0C, Luo\u00a0AY (2007) Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J\u00a0Rheumatol 34(2):272\u2013279","journal-title":"J Rheumatol"},{"issue":"2","key":"5704_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ibd\/izx001","volume":"24","author":"PK Pratt Jr","year":"2018","unstructured":"Pratt\u00a0PK Jr, David\u00a0N, Weber\u00a0HC, Little\u00a0FF, Kourkoumpetis\u00a0T, Patts\u00a0GJ, Weinberg\u00a0J, Farraye\u00a0FA (2018) Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Inflamm Bowel Dis 24(2):380\u2013386. https:\/\/doi.org\/10.1093\/ibd\/izx001","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"5704_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/ddg.14156_g","volume":"18","author":"S Mohme","year":"2020","unstructured":"Mohme\u00a0S, Schmalzing\u00a0M, M\u00fcller\u00a0CSL, Vogt\u00a0T, Goebeler\u00a0M, Stoevesandt\u00a0J (2020) Impfen bei Immunsuppression: ein Leitfaden f\u00fcr die dermatologische Praxis. J\u00a0Dtsch Dermatol Ges 18(7):699\u2013725. https:\/\/doi.org\/10.1111\/ddg.14156_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"5704_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.17886\/EpiBull-2017-059.2","volume":"50","author":"St\u00e4ndige Impfkommission (STIKO)","year":"2018","unstructured":"St\u00e4ndige Impfkommission (STIKO) (2018) Wissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epid Bull 50:541\u2013567. https:\/\/doi.org\/10.17886\/EpiBull-2017-059.2","journal-title":"Epid Bull"},{"key":"5704_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/13540.2","volume":"45","author":"J Judith Koch","year":"2025","unstructured":"Judith Koch\u00a0J, Hermanns\u00a0S, Wilhelm\u00a0J, Dalpke\u00a0A, Hengel\u00a0H, Karch\u00a0A, Lange\u00a0B, M\u00fcller\u00a0B, Oberle\u00a0D, von Bernuth\u00a0H, Wiedermann-Schmidt\u00a0U, Ciesek\u00a0S, Tabatabai\u00a0J (2025) Beschluss und wissenschaftliche Begr\u00fcndung f\u00fcr die Erweiterung der Indikationsimpfempfehlung zur Herpes-zoster-Impfung mit dem adjuvantierten Subunit-Totimpfstoff f\u00fcr Personen \u2265\u202f18 Jahre mit einem erh\u00f6hten Risiko, an Herpes zoster zu erkranken. Epid Bull 45:3\u201327. https:\/\/doi.org\/10.25646\/13540.2","journal-title":"Epid Bull"},{"key":"5704_CR40","unstructured":"Deutsche Dermatologische Gesellschaft (DDG) (2025) S3-Leitlinie \u201eTherapie der Psoriasis vulgaris\u201c (AWMF-Registernummer 013 - 001). Version 8.0. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/013-001. Letzter Zugriff am 2.1.2026"},{"issue":"1","key":"5704_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bjd\/ljaf101","volume":"193","author":"CN Lee","year":"2025","unstructured":"Lee\u00a0CN, Hsieh\u00a0MH, Chen\u00a0CY, Yang\u00a0CC, Liao\u00a0TC, Lai\u00a0EC (2025) Risk of herpes zoster and postherpetic neuralgia in patients with psoriasis treated with biologics: a\u00a0nationwide study using a\u00a0target trial emulation framework. Br J Dermatol 193(1):105\u2013114. https:\/\/doi.org\/10.1093\/bjd\/ljaf101","journal-title":"Br J Dermatol"},{"issue":"2","key":"5704_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000072","volume":"2","author":"D D\u2019Arienzo","year":"2021","unstructured":"D\u2019Arienzo\u00a0D, Noya\u00a0RG, Morinville\u00a0F, Disseminated\u00a0VD (2021) Disseminated and Central Nervous System Vaccine-Strain Herpes Zoster Infection in a Teenager With Crohn\u2019s Disease on Maintenance Adalimumab Therapy. JPGN Rep 2(2):e072. https:\/\/doi.org\/10.1097\/PG9.0000000000000072","journal-title":"JPGN Rep"},{"issue":"2","key":"5704_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.idc.2020.02.006","volume":"34","author":"DY Ho","year":"2020","unstructured":"Ho\u00a0DY, Enriquez\u00a0K, Multani\u00a0A (2020) Herpesvirus Infections Potentiated by Biologics. Infect Dis Clin North Am 34(2):311\u2013339. https:\/\/doi.org\/10.1016\/j.idc.2020.02.006","journal-title":"Infect Dis Clin North Am"},{"key":"5704_CR44","unstructured":"Schaberg T, Brinkmann F, Feiterna-Sperling C, Geerdes-Fenge H, Hartmann P, H\u00e4cker B, Hauer B, Haas W, Heyckendorf J, C C, Maurer FP, Nienhaus A, Knapp RO, Priwitzer M, Richter E, Salzer HJF, Schoch O, Sch\u00f6nfeld N, Stahlmann R, Bauer T (2022) S2k-Leitlinie zur Diagnostik und Therapie, Chemopr\u00e4vention und Chemoprophylaxe der Tuberkulose im Erwachsenenalter des Deutschen Zentralkomitees zur Bek\u00e4mpfung der Tuberkulose e.\u202fV. (DZK) und der Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e.\u202fV. (DGP). Erstver\u00f6ffentlichung 2017, aktuelles Update 2022 Version 2.4. https:\/\/register.awmf.org\/assets\/guidelines\/020-019l_S2k_Tuberkulose-im-Erwachsenenalter_2023-09.pdf. Letzter Zugriff am 25.1.2026"},{"issue":"5","key":"5704_CR45","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1183\/09031936.00120908","volume":"33","author":"U Mack","year":"2009","unstructured":"Mack\u00a0U, Migliori\u00a0GB, Sester\u00a0M, Rieder\u00a0HL, Ehlers\u00a0S, Goletti\u00a0D, Bossink\u00a0A, Magdorf\u00a0K, H\u00f6lscher\u00a0C, Kampmann\u00a0B, Arend\u00a0SM, Detjen\u00a0A, Bothamley\u00a0G, Zellweger\u00a0JP, Milburn\u00a0H, Diel\u00a0R, Ravn\u00a0P, Cobelens\u00a0F, Cardona\u00a0PJ, Kan\u00a0B, Solovic\u00a0I, Duarte\u00a0R, Cirillo\u00a0DM, Lange\u00a0C, TBNET (2009) LTBI: latent tuberculosis infection or lasting immune responses to M.\u00a0tuberculosis? A\u00a0TBNET consensus statement. Eur Respir\u00a0J 33(5):956\u2013973. https:\/\/doi.org\/10.1183\/09031936.00120908","journal-title":"Eur Respir J"},{"issue":"23","key":"5704_CR46","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling\u00a0TR, Villarino\u00a0ME, Borisov\u00a0AS, Shang\u00a0N, Gordin\u00a0F, Bliven-Sizemore\u00a0E, Hackman\u00a0J, Hamilton\u00a0CD, Menzies\u00a0D, Kerrigan\u00a0A, Weis\u00a0SE, Weiner\u00a0M, Wing\u00a0D, Conde\u00a0MB, Bozeman\u00a0L, Horsburgh\u00a0CR Jr, Chaisson\u00a0RE, TB Trials Consortium PREVENT TB Study Team (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. N\u00a0Engl J Med 365(23):2155\u20132166. https:\/\/doi.org\/10.1056\/NEJMoa1104875","journal-title":"N Engl J Med"},{"issue":"5","key":"5704_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies\u00a0D, Adjobimey\u00a0M, Ruslami\u00a0R, Trajman\u00a0A, Sow\u00a0O, Kim\u00a0H, Obeng Baah\u00a0J, Marks\u00a0GB, Long\u00a0R, Hoeppner\u00a0V, Elwood\u00a0K, Al-Jahdali\u00a0H, Gninafon\u00a0M, Apriani\u00a0L, Koesoemadinata\u00a0RC, Kritski\u00a0A, Rolla\u00a0V, Bah\u00a0B, Camara\u00a0A, Boakye\u00a0I, Cook\u00a0VJ, Goldberg\u00a0H, Valiquette\u00a0C, Hornby\u00a0K, Dion\u00a0MJ, Li\u00a0PZ, Hill\u00a0PC, Schwartzman\u00a0K, Benedetti\u00a0A (2018) Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N\u00a0Engl J Med 379(5):440\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1714283","journal-title":"N Engl J Med"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05704-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:34:10Z","timestamp":1783074850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05704-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5704"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05704-3","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"29 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"G.\u00a0Balakirski\n                      : A.\u00a0Finanzielle Interessen: Priv.-Doz. Dr. med. Galina Balakirski received advisor, speaker, or investigator fees from AbbVie, Almirall, Amgen, AOP Health, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin im Zentrum f\u00fcr Dermatologie, Allergologie und Dermatochirurgie, Helios Universit\u00e4tsklinikum Wuppertal, Universit\u00e4t Witten\/Herdecke, Wuppertal | Mitgliedschaften bei folgenden Fachgruppen: DDG, DGDC, EADV, EAACI, DGAKI, IDDG, ADI-TD.\n                      P.\u00a0Nenoff\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare von AbbVie, Almirall Hermal, bioM\u00e9rieux, Beiersdorf, Galderma, Janssen, MSD, Novartis, Dr. Pfleger, Pfizer, Sanofi Genzyme, and UCB Pharma.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassener Laborarzt in eigener Praxis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}